Overall rank by patents
#28,127
Across all tracked assignees
USPTO PatentsView assignee record - 9 granted patents across 6 technology areas, active 2017–2024. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61F (FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICE).
The verdict
Aneumed holds 9 US patents across 6 technology areas, rank #28,127 of 50,000 tracked assignees.
Aneumed, Inc. has been granted 9 US utility patents between 2017 and 2024, placing Aneumed, Inc. at rank #28,127 across all assignees tracked by PlainPatent. This portfolio spans 6 distinct Cooperative Patent Classification (CPC) subclasses, averaging 18.6 claims per patent with primary concentration in A61F (FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICE). As a US Corporation, Aneumed, Inc. is one of the more focused assignees in the PatentsView dataset. By volume, Aneumed sits between Amunix Pharmaceuticals, Inc. (9 patents, rank #28,123) and Annexon, Inc. (9 patents, rank #28,131) - the closest US assignees by grant volume. The composite Innovation Score of 30.0/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 3 grants, compared with 6 in the 2015–2019 window, a -50% shift in five-year velocity. A cooling filing rate may reflect portfolio consolidation, shifting priorities, or reduced R&D throughput. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Aneumed, Inc.'s 18.6 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while concentration in 6 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Aneumed, Inc. against peers pursuing similar technology classes.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
Amunix Pharmaceuticals, Inc.
9 patents
Analog Value Ltd.
9 patents
Analysis and Measurement Services Corp.
9 patents
Analytical Graphics Inc.
9 patents
Angiochem Inc.
9 patents
Anji Leisa Furniture Co., Ltd.
9 patents
Anji Weiyu Furniture Co., Ltd.
9 patents
Annexon, Inc.
9 patents
AneuMed, Inc.
9 patents
What this shows Aneumed holds 9 patents at rank #28,127, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
By rank, the assignees closest to #28,127 in granted patent volume.
Other assignees with the most granted patents in Aneumed's primary technology class.
Aneumed's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
30 Top 67% higher than 33% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2017–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2017 | 5 | 55.6% |
| 2019 | 1 | 11.1% |
| 2020 | 2 | 22.2% |
| 2024 | 1 | 11.1% |
Top 6 of 6 technology areas
Overall rank by patents
#28,127
Across all tracked assignees
30.0 out of 100
How to use this portfolio
Aneumed's 9 grants land it in the top 67% by Innovation Score, but volume alone doesn't tell you where the strength sits.
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.